HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions.

AuthorsJost B Jonas, Teodosio Libondi, Frank Schlichtenbrede, Matthias Schmidbauer
JournalActa ophthalmologica (Acta Ophthalmol) Vol. 88 Issue 2 Pg. e24-5 (Mar 2010) ISSN: 1755-3768 [Electronic] England
PMID19493250 (Publication Type: Case Reports, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Triamcinolone Acetonide
Topics
  • Aged
  • Angiogenesis Inhibitors (administration & dosage)
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Fluorescein Angiography
  • Glaucoma, Angle-Closure (drug therapy, etiology)
  • Glucocorticoids (administration & dosage)
  • Humans
  • Injections
  • Intraocular Pressure (drug effects)
  • Iris (blood supply)
  • Neovascularization, Pathologic (drug therapy, etiology)
  • Retinal Vein Occlusion (complications, drug therapy)
  • Retrospective Studies
  • Triamcinolone Acetonide (administration & dosage)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (physiology)
  • Vitreous Body

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: